ReviewMolecular medicine reports2025
The key role of miR‑378 in kidney diseases (Review).
Review in Molecular medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs/miRs) are endogenous, small non‑coding RNAs conserved across species that post‑transcriptionally regulate gene expression by both suppressing translation and inducing mRNA degradation. miRNAs are found in various tissues, exhibit variable expression and their dysregulation is implicated in numerous disease processes. Furthermore, miRNA expression levels have a key role in the normal development of kidney tissue and are key regulators of kidney function, modulating diverse biological processes across renal cell lineages. miR‑378 participates in pathological processes associated with kidney diseases, including kidney cancer, kidney transplantation and diabetic nephropathy. Despite its considerable effects on these conditions, a comprehensive summary of the roles of miR‑378 is unavailable. In the present review, the existing literature on miR‑378 in kidney diseases is consolidated, and its validated gene targets and biological effects in both malignant and non‑malignant conditions are highlighted, thereby providing a foundation for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.